HOMA-IR and QUICKI: decide on a general standard instead of making further comparisons.

Department of Woman and Child Health, Division of Pediatrics, Karolinska Institute, Stockholm, Sweden.
Acta Paediatrica (Impact Factor: 1.97). 11/2010; 99(11):1735-40. DOI: 10.1111/j.1651-2227.2010.01911.x
Source: PubMed

ABSTRACT To limit further comparisons between the two fasting indices Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI), and to examine their robustness in assessing insulin sensitivity.
A total of 191 obese children and adolescents (age 13.9 ± 2.9 years, BMI SDS 6.1 ± 1.6), who had undergone a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), were included. Receiver operating characteristic curve (ROC) analysis was used to compare indices in detecting insulin resistance and Bland-Altman plots to investigate agreement between three consecutive fasting samples when compared to using single samples.
ROC analysis showed that the diagnostic accuracy was identical for QUICKI and HOMA-IR [area under the curve (AUC) boys 0.80, 95%CI 0.70-0.89; girls 0.80, 0.71-0.88], while insulin had a nonsignificantly lower AUC (boys 0.76, 0.66-0.87; girls 0.75, 0.66-0.84). Glucose did not perform better than chance as a diagnostic test (boys 0.47, 0.34-0.60; girls 0.57, 0.46-0.68). Indices varied with consecutive sampling, mainly attributable to fasting insulin variations (mean maximum difference in HOMA-IR -0.8; -0.9 to -0.7).
Using both HOMA-IR and QUICKI in further studies is superfluous as these indices function equally well as predictors of the FSIVGTT sensitivity index. Focus should be on establishing a general standard for research and clinical purposes.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background: An increased relative risk of diabetes, ischemic heart disease, atherosclerosis, and hypertension have been reported in Turner syndrome (TS) patients. No data are currently available on the prevalence of metabolic syndrome in TS subjects. We evaluated the frequency of metabolic syndrome in obese and nonobese patients with TS. Patients and Methods: We evaluated 85 TS patients (27.05±11.17 years). Obesity was defined as standard deviation score body mass index (SDS-BMI) ≥2 or BMI ≥30 kg/m(2) in adult patients. We classified metabolic syndrome according to the International Diabetes Federation (IDF). Hepatic ultrasound was performed in all girls. Results: The prevalence of metabolic syndrome was 4.7% (12.5% obese and 4.3% nonobese, P=0.16) and associated with visceral adiposity (P=0.008). Abnormalities in glucose metabolism and hypertension were not associated with genetic or therapeutic factors. The karyotype 45,X was associated with atherogenic profile. Pathological waist circumference was more frequent in girls treated with estro-progestin (P=0.03). Evidence of fatty liver was associated with metabolic syndrome (P=0.03) and insulin resistance (P=0.05). Elevated liver enzymes were found in 15 subjects and were not related to treatment or ultrasound abnormalities. Conclusions: Prevalence of each component of metabolic syndrome in TS patients is partially influenced by genetic makeup and treatment. Hepatosteatosis was associated with metabolic syndrome and insulin resistance, but not to elevated liver enzymes.
    Metabolic syndrome and related disorders 01/2014; · 1.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies have indicated that ApoB/ApoA-I ratio is significantly associated with MetS and IR. This study was designedto assess the optimal cutoff values of ApolipoproteinB/ApolipoproteinA-I (ApoB/ApoA-I) ratio for the diagnosis of metabolic syndrome and insulin resistance (IR) in the population of Georgia. The subjects were 1522 Georgians of Caucasian origin aged 18-80 (653 women and 869 men) without diabetes mellitus. MetS was diagnosed using the updated ATP-III definition of the metabolic syndrome. Receiver operating characteristics (ROC) curve analysis was performed to calculate the cutoff values. ROC analysis showed that areas under the curve (AUCs) of ApoB/ApoA-I ratio for the detection of MetS were 0.786±0.025 (95%CI: 0.737-0.834) in women and 0.815±0.017 (95%CI: 0.782-0.847) in men. AUCs of ApoB/ApoA-I ratio for the diagnosis of IR were 0.887±0.019 (95%CI: 0.850-0.924) in women and 0.816±0.022 (95%CI: 0.773-0.860) in men. After adjustment for age, MetS components and low-density lipoprotein cholesterol, odds ratios according to the determined cutoff values of ApoB/ApoA-I ratio were: for MetS – 1.75 in women and 1.18 in men; for IR – 13.61 in women and 7.75 in men.
    International Journal of Sciences: Basic and Applied Research (IJSBAR) 08/2014; 17(2):224-235.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atypical antipsychotics have become a common therapeutic option in both schizophrenia and bipolar disorder. However, these medications come with a high risk of metabolic side effects, particularly dyslipidemia and insulin resistance. Therefore, identification of patients who are at increased risk for metabolic side effects is of great importance. The genetics of fatty acid metabolism is one area of research that may help identify such patients. Therefore, in this present study, we aimed to determine the effect of one commonly studied genetic polymorphism from both fatty acid desaturase 1 (FADS1) and FADS2 gene on a surrogate measure of insulin resistance and lipid levels in a metabolically high-risk population of patients largely exposed to atypical antipsychotics. This study used a cross-sectional design, fasting blood draws, and genetic analysis to investigate associations between polymorphisms, haplotypes, and metabolic measures. A total of 320 subjects with schizophrenia (n = 226) or bipolar disorder (n = 94) were included in this study. The mean age of the population was 42.5 years and 45% were male. A significant association between FADS1 and FADS2 haplotypes was found with insulin resistance while controlling for confounders. Further investigation is required to replicate this finding.
    Cardiovascular Psychiatry and Neurology 01/2013; 2013:596945.